{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:03:29Z","timestamp":1780297409966,"version":"3.54.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["AI 118389"],"award-info":[{"award-number":["AI 118389"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127779","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:04:35Z","timestamp":1758765875000},"page":"127779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nontoxic, multi-domain botulinum neurotoxin-LCHCN as vaccines against botulism."],"prefix":"10.1016","volume":"65","author":[{"given":"A.","family":"Przedpelski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"Tepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pellett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2025.127779_bb0005","doi-asserted-by":"crossref","first-page":"2205251","DOI":"10.1080\/21505594.2023.2205251","article-title":"Pathogenicity and virulence of Clostridium botulinum","volume":"14","author":"Rawson","year":"2023","journal-title":"Virulence"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127779_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11120681","article-title":"Biosecurity threat posed by botulinum toxin","volume":"11","author":"Cenciarelli","year":"2019","journal-title":"Toxins (Basel)."},{"issue":"42","key":"10.1016\/j.vaccine.2025.127779_bb0015","first-page":"1454","article-title":"Notice of CDC'S discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins","volume":"60","author":"Centers for Disease C, Prevention.","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127779_bb0020","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1006\/jmbi.1999.2945","article-title":"Sequence homology and structural analysis of the clostridial neurotoxins","volume":"291","author":"Lacy","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2025.127779_bb0025","first-page":"1","article-title":"Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes","volume":"364","author":"Hill","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127779_bb0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127779_bb0035","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: past history and recent developments","volume":"5","author":"Rusnak","year":"2009","journal-title":"Hum Vaccin"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127779_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erv.13.37","article-title":"What next for botulism vaccine development?","volume":"12","author":"Webb","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"33","key":"10.1016\/j.vaccine.2025.127779_bb0045","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.vaccine.2009.05.030","article-title":"Production of catalytically inactive BoNT\/A1 holoprotein and comparison with BoNT\/A1 subunit vaccines against toxin subtypes A1, A2, and A3","volume":"27","author":"Webb","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127779_bb0050","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.vaccine.2017.12.064","article-title":"Enhancing toxin-based vaccines against botulism","volume":"36","author":"Przedpelski","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127779_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14020135","article-title":"Functional EL-HN fragment as a potent candidate vaccine for the Prevention of botulinum neurotoxin serotype E","volume":"14","author":"Li","year":"2022","journal-title":"Toxins (Basel)."},{"issue":"2","key":"10.1016\/j.vaccine.2025.127779_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1046-5928(02)00002-5","article-title":"Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type a","volume":"25","author":"Chaddock","year":"2002","journal-title":"Protein Expr Purif"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127779_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/IAI.00843-07","article-title":"Recombinant holotoxoid vaccine against botulism","volume":"76","author":"Pier","year":"2008","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127779_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9090269","article-title":"Recombinant botulinum neurotoxin Hc subunit (BoNT Hc) and catalytically inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as vaccine candidates for the Prevention of botulism","volume":"9","author":"Webb","year":"2017","journal-title":"Toxins (Basel)"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127779_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15090563","article-title":"Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines","volume":"15","author":"Gupta","year":"2023","journal-title":"Toxins"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127779_bb0080","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/IAI.01025-07","article-title":"Subunit vaccine against the seven serotypes of botulism","volume":"76","author":"Baldwin","year":"2008","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127779_bb0085","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.toxicon.2009.02.034","article-title":"Immune recognition of BoNTs a and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action","volume":"54","author":"Atassi","year":"2009","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127779_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imbio.2011.09.001","article-title":"Antibody and T cell recognition of the light chain of botulinum neurotoxin a in two high-responder mouse strains","volume":"217","author":"Atassi","year":"2012","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127779_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10030105","article-title":"A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype E subtypes","volume":"10","author":"Garcia-Rodriguez","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2025.127779_bb0100","doi-asserted-by":"crossref","first-page":"15776","DOI":"10.1038\/srep15776","article-title":"Antigenic sites on the HN domain of botulinum neurotoxin a stimulate protective antibody responses against active toxin","volume":"5","author":"Ayyar","year":"2015","journal-title":"Sci Rep"},{"issue":"Pt A","key":"10.1016\/j.vaccine.2025.127779_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.toxicon.2015.06.003","article-title":"Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions","volume":"107","author":"Atassi","year":"2015","journal-title":"Toxicon"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127779_bb0110","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/IAI.01252-08","article-title":"Bivalent recombinant vaccine for botulinum neurotoxin types a and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant a and B subtypes","volume":"77","author":"Shone","year":"2009","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127779_bb0115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/21645515.2019.1633878","article-title":"Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E","volume":"16","author":"Shi","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127779_bb0120","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s12640-021-00337-x","article-title":"Recombinant L-HN fusion antigen derived from the L and HN domains of botulinum neurotoxin B stimulates a protective antibody response against active neurotoxin","volume":"39","author":"Li","year":"2021","journal-title":"Neurotox Res"},{"issue":"16","key":"10.1016\/j.vaccine.2025.127779_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168955","article-title":"Potency evaluations of recombinant botulinum neurotoxin A1 mutants designed to reduce toxicity","volume":"25","author":"Viravathana","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2025.127779_bb0130","first-page":"4","volume":"11","author":"Przedpelski","year":"2020","journal-title":"A Novel High-Potency Tetanus Vaccine mBio"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127779_bb0135","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/IAI.00536-13","article-title":"Characterization of botulinum neurotoxin a subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro","volume":"81","author":"Whitemarsh","year":"2013","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127779_bb0140","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/iai.55.7.1647-1651.1987","article-title":"Expression of a mutant, full-length form of diphtheria toxin in Escherichia coli","volume":"55","author":"Barbieri","year":"1987","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127779_bb0145","first-page":"27","article-title":"Purification of Clostridium botulinum type a neurotoxin","volume":"145","author":"Malizio","year":"2000","journal-title":"Methods in molecular biology (Clifton, NJ)"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127779_bb0150","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1074\/jbc.M611211200","article-title":"Mechanism of substrate recognition by botulinum neurotoxin serotype a","volume":"282","author":"Chen","year":"2007","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127779_bb0155","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type a and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat Struct Biol"},{"issue":"18","key":"10.1016\/j.vaccine.2025.127779_bb0160","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1021\/bi3000098","article-title":"Insights into the different catalytic activities of Clostridium neurotoxins","volume":"51","author":"Chen","year":"2012","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127779_bb0165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/78005","article-title":"Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B","volume":"7","author":"Swaminathan","year":"2000","journal-title":"Nat Struct Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127779_bb0170","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/jb.108.3.1051-1057.1971","article-title":"Activation of Clostridium botulinum type B toxin by an endogenous enzyme","volume":"108","author":"DasGupta","year":"1971","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2025.127779_bb0175","series-title":"Select Agents and Toxins Exclusions: Nontoxic HHS toxins (Section 73.3 (d)(2)). In: Compliance DoRSa, ed. 1600 Clifton Road, NE, Mailstop H21\u20134 Atlanta, GA 30329: CDC and USDA","author":"Program","year":"2025"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127779_bb0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/imm.13867","article-title":"New engineered-chimeric botulinum neurotoxin mutant acts as an effective bivalent vaccine against botulinum neurotoxin serotype a and E","volume":"174","author":"Wang","year":"2025","journal-title":"Immunology"},{"issue":"23","key":"10.1016\/j.vaccine.2025.127779_bb0185","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1007\/s00253-023-12796-7","article-title":"Tetanus toxin and botulinum neurotoxin-derived fusion molecules are effective bivalent vaccines","volume":"107","author":"Li","year":"2023","journal-title":"Appl Microbiol Biotechnol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127779_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10060231","article-title":"Engineering of botulinum neurotoxins for biomedical applications","volume":"10","author":"Webb","year":"2018","journal-title":"Toxins (Basel)."},{"issue":"3","key":"10.1016\/j.vaccine.2025.127779_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15030200","article-title":"Biological and immunological characterization of a functional L-HN derivative of botulinum neurotoxin serotype F","volume":"15","author":"Li","year":"2023","journal-title":"Toxins (Basel)."},{"key":"10.1016\/j.vaccine.2025.127779_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2023.102764","article-title":"Biology activity and characterization of the functional L-HN fragment derivative of botulinum neurotoxin serotype E","volume":"82","author":"Tan","year":"2023","journal-title":"Anaerobe"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127779_bb0205","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/jpet.108.136242","article-title":"The role of systemic handling in the pathophysiologic actions of botulinum toxin","volume":"326","author":"Al-Saleem","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127779_bb0210","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112095","article-title":"Presynaptic targeting of botulinum neurotoxin type a requires a tripartite PSG-Syt1-SV2 plasma membrane nanocluster for synaptic vesicle entry","volume":"42","author":"Joensuu","year":"2023","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127779_bb0215","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1471-4159.1991.tb08253.x","article-title":"Binding of botulinum and tetanus neurotoxins to ganglioside GT1b and derivatives thereof","volume":"57","author":"Schengrund","year":"1991","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127779_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15050316","article-title":"A three-monoclonal antibody combination potently neutralizes BoNT\/G toxin in mice","volume":"15","author":"Fan","year":"2023","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127779_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13010031","article-title":"A monoclonal antibody combination against both serotypes a and B botulinum toxin prevents inhalational botulism in a Guinea pig model","volume":"13","author":"Snow","year":"2021","journal-title":"Toxins"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127779_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13090671","article-title":"Neutralizing concentrations of anti-botulinum toxin antibodies positively correlate with mouse neutralization assay results in a Guinea pig model","volume":"13","author":"Tomic","year":"2021","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127779_bb0235","doi-asserted-by":"crossref","first-page":"20806","DOI":"10.1038\/s41598-023-48008-5","article-title":"A human bispecific antibody neutralizes botulinum neurotoxin serotype a","volume":"13","author":"Lu","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127779_bb0240","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1542\/peds.2006-0645","article-title":"Clinical mimics of infant botulism","volume":"119","author":"Francisco","year":"2007","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127779_bb0245","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1021\/bi992321x","article-title":"Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain","volume":"39","author":"Li","year":"2000","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127779_bb0250","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/bi0157969","article-title":"Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization","volume":"41","author":"Binz","year":"2002","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127779_bb0255","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00244-20","article-title":"Tetanus Toxin cis-Loop Contributes to Light-Chain Translocation","volume":"5","author":"Zuverink","year":"2020","journal-title":"mSphere"},{"issue":"16","key":"10.1016\/j.vaccine.2025.127779_bb0260","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M513032200","article-title":"Unique substrate recognition by botulinum neurotoxins serotypes A and E","volume":"281","author":"Chen","year":"2006","journal-title":"J Biol Chem"},{"issue":"30","key":"10.1016\/j.vaccine.2025.127779_bb0265","doi-asserted-by":"crossref","first-page":"21153","DOI":"10.1074\/jbc.M800611200","article-title":"Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin","volume":"283","author":"Chen","year":"2008","journal-title":"J Biol Chem"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2501076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:48:10Z","timestamp":1780296490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2501076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"alternative-id":["S0264410X2501076X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127779","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nontoxic, multi-domain botulinum neurotoxin-LCHCN as vaccines against botulism.","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127779"}}